Itronia Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is commonly prescribed for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itronia Capsule is administered orally and demonstrates good bioavailability, with absorption enhanced when taken with food. The drug undergoes hepatic metabolism primarily via the cytochrome P450 3A4 pathway, necessitating caution when co-administered with other medications metabolized by this enzyme to avoid potential drug interactions. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as headache and dizziness. Liver function monitoring is recommended during prolonged therapy due to the risk of hepatotoxicity. Itronia Capsule should be used with caution in patients with hepatic impairment and contraindicated in individuals with known hypersensitivity to itraconazole or other azole antifungals. Proper adherence to prescribed dosage and duration is essential to ensure therapeutic efficacy and minimize resistance development.